Clinical trial • Other
DEXMEDETOMIDINE for Procedural sedation | Procedural pain
Clinical trial of DEXMEDETOMIDINE for Procedural sedation | Procedural pain.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Procedural sedation | Procedural pain
- Drug Modality
- Small molecule
- Paediatric Trial
- Yes
Key dates
- Initial CTIS Submission Date
- 08-10-2024
- First CTIS Authorization Date
- 05-11-2024
Trial design
Randomised, sodium chloride (placebo) intranasal, delivered using mad nasal™ intranasal mucosal atomization device; product max total amount indicated as 1 ml (placebo).-controlled trial across 1 site in Finland.
- Randomised
- Yes
- Comparator
- Sodium chloride (placebo) intranasal, delivered using MAD Nasal™ Intranasal Mucosal Atomization Device; product max total amount indicated as 1 ml (placebo).
- Target Sample Size
- 112
- Trial Duration For Participant
- 1
Eligibility
Recruits 112 paediatric patients.
- Vulnerable Population
- Includes pediatric participants aged 1-12; vulnerable population selected. Informed consent is obtained from parent(s). Age-appropriate informed consent/assent forms are provided (documents listed: "Informed consent, parent"; "Informed consent, 6-9 years of age"; "Informed consent, 10-12 years of age"). Documents/translations available in Finnish.
Inclusion criteria
- {"criterion_text":"- Age 1-12 years\n- Small procedure (e.g. i.v. cannulation or lumbar puncture)\n- Presents at the Oulu University Hospital emergency room"}
Exclusion criteria
- {"criterion_text":"- Allergy to dexmedetomidine or any supplementary elements of the dexmedetomidine-solution\n- II or III degree AV-blockage without pacemaker\n- Uncontrollable hypotension\n- Stroke\n- Critically ill patients who are admitted to the Pediatric Intensive Care Unit\n- Patients with clear cardiac or respiratory dysfunction\n- Lowered level of consciousness\n- Patients with increased risk of apnoeic events due to neurologic or metabolic conditions or extreme obesity\n- Prior participation to the current study"}
Endpoints
Primary endpoints
- {"endpoint_text":"- The success of the procedure at the first attempt","definition_or_measurement_approach":""}
Secondary endpoints
- {"endpoint_text":"- The duration of the procedure","definition_or_measurement_approach":""}
- {"endpoint_text":"- Parents assessment of the patients comfortability during the procedure","definition_or_measurement_approach":"Parents' assessment using a Likert scale (as indicated in translations)."}
- {"endpoint_text":"- Patient's and physician's assessment of the experienced pain with Visual Analog Scale","definition_or_measurement_approach":"Pain assessed by patient and physician using Visual Analog Scale (VAS)."}
- {"endpoint_text":"- Assessment of pain levels of the patient with FLACC-scores","definition_or_measurement_approach":"Pain assessed using FLACC score."}
- {"endpoint_text":"- Assessment of sedation levels of the patient with Comfort-B-scores","definition_or_measurement_approach":"Sedation assessed using the COMFORT-B sedation scale."}
- {"endpoint_text":"- Duration of crying","definition_or_measurement_approach":"Measured in minutes from the moment the patient receives the intranasal study drug until the procedure is successfully completed."}
- {"endpoint_text":"- The parents and the emergency room nurses are asked whether they think the patient recieved the experimental drug or placebo","definition_or_measurement_approach":"Parental and nurse assessment of perceived treatment allocation (experimental drug vs placebo)."}
- {"endpoint_text":"- Blood pressure measured by manometer","definition_or_measurement_approach":"Blood pressure measurement by manometer."}
- {"endpoint_text":"- Respiratory rate assessed by capnometry","definition_or_measurement_approach":"Respiratory rate measured by capnometry."}
- {"endpoint_text":"- Oxygen saturation is measured by pulse oxymetry","definition_or_measurement_approach":"Oxygen saturation measured by pulse oximetry."}
- {"endpoint_text":"- Heart rate measured by ECG","definition_or_measurement_approach":"Heart rate measured by ECG."}
Recruitment
- Planned Sample Size
- 112
- Recruitment Window Months
- 141
- Consent Approach
- Parental informed consent required. Age-appropriate assent/information forms provided: separate documents for 'Informed consent, parent', 'Informed consent, 6-9 years of age', and 'Informed consent, 10-12 years of age'. Documents/translations available in Finnish.
Methods
- Patients presenting to the Oulu University Hospital pediatric emergency room who require a minor painful procedure (e.g. IV cannulation or lumbar puncture) are approached and asked to join the study at the point of care in the emergency room (site: Finland, Oulu University Hospital).
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 112
Finland
- Earliest CTIS Part Ii Submission Date
- 18-10-2024
- Latest Decision Or Authorization Date
- 05-11-2024
- Processing Time Days
- 18
- Number Of Sites
- 1
- Number Of Participants
- 112
Sites
- Site Name
- Oulu University Hospital
- Department Name
- Department of Pediatrics and Adolescence
- Contact Person Name
- Outi Peltoniemi
- Contact Person Email
- outi.peltoniemi-ailisto@pohde.fi
- Number Of Participants
- 112
Sponsor
Primary sponsor
- Full Name
- Oulu University Hospital
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Finland
Investigational products
- Investigational Product Name
- DEXMEDETOMIDINE
- Active Substance
- DEXMEDETOMIDINE
- Modality
- Small molecule
- Routes Of Administration
- INTRANASAL USE
- Route
- INTRANASAL USE
- Starting Dose
- 1 μg/kg
- Dose Levels
- 1 μg/kg
- Frequency
- Single administration
- Maximum Dose
- 100 µg
- Investigational Product Name
- SODIUM CHLORIDE
- Active Substance
- SODIUM CHLORIDE
- Modality
- Small molecule
- Routes Of Administration
- INTRANASAL USE
- Route
- INTRANASAL USE
- Starting Dose
- up to 1 ml (placebo, max total amount indicated)
- Dose Levels
- up to 1 ml
- Frequency
- Single administration
- Maximum Dose
- 1 ml
Related trials
Other published trials that may interest you.